Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

290.91 +7.40 (+2.61%)

Streaming Delayed Price Updated: 12:18 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health

Today 7:00 EST

From Insulet Corporation

Via Business Wire

2 Mid-Cap Stocks to Own for Decades and 1 That Underwhelm

December 30, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

Topics Artificial Intelligence

Insulet Corp (NASDAQ:PODD) Presents a Classic Growth at a Reasonable Price (GARP) Case ↗

December 29, 2025

Insulet Corp (PODD) exemplifies Growth at a Reasonable Price (GARP) with strong earnings growth, solid financials, and a valuation justified by its sector and future potential.

Via Chartmill

Insulet Corp (NASDAQ:PODD) Passes Key Growth Stock Screen from "The Little Book That Makes You Rich" ↗

December 23, 2025

Insulet Corp (PODD) exemplifies a high-growth stock, meeting key criteria for accelerating earnings, sales, and cash flow with strong profitability.

Via Chartmill

Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

From Insulet Corporation

Via Business Wire

Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future

December 15, 2025

From Insulet Corporation

Via Business Wire

Patient Monitoring Stocks Q3 In Review: Insulet (NASDAQ:PODD) Vs Peers

December 08, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.

Via StockStory

Topics Artificial Intelligence

Friday's session: top gainers and losers in the S&P500 index ↗

December 05, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

These S&P500 stocks are moving in today's session ↗

December 05, 2025

Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

2 High-Flying Stocks with Impressive Fundamentals and 1 We Turn Down

December 04, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

Topics Energy

Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

December 04, 2025

From Insulet Corporation

Via Business Wire

Insulet Corp. (NASDAQ:PODD) Embodies a Proven Growth Investing Strategy ↗

December 02, 2025

Insulet Corp. exemplifies a disciplined growth investing strategy, showcasing accelerating revenue, earnings, and cash flow that meet strict financial filters for stock selection.

Via Chartmill

2 Growth Stocks with Explosive Upside and 1 We Find Risky

December 01, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

Exploring the top movers within the S&P500 index during today's session. ↗

December 01, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

Discover which S&P500 stocks are making waves on Monday. ↗

December 01, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

3 Quality Compounders to Keep an Eye On

December 01, 2025

Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more profits. Rinse and repeat.

Via StockStory

Which S&P500 stocks are moving on Tuesday? ↗

November 25, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...

Via StockStory

Topics Economy

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 21, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

November 20, 2025

Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.

Via Chartmill

Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day

November 20, 2025

From Insulet Corporation

Via Business Wire

Peering Into Insulet Corp's Recent Short Interest ↗

November 20, 2025

Via Benzinga

Insulet Corp (NASDAQ:PODD) Presents a Compelling Affordable Growth Opportunity ↗

November 20, 2025

Insulet Corp (PODD) offers strong growth and profitability at a reasonable valuation. Its solid financial health makes it a top affordable growth stock.

Via Chartmill

$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today ↗

November 19, 2025

Via Benzinga

3 Reasons We Love Insulet (PODD)

November 18, 2025

Since May 2025, Insulet has been in a holding pattern, posting a small return of 3% while floating around $335.74. The stock also fell short of the S&P 500’s 11.9% gain during that period.

Via StockStory

Topics Stocks

Insulet Corp (PODD) Shows Strong Technical and Fundamental Momentum ↗

November 18, 2025

Discover how Insulet Corp (PODD) combines strong technical uptrends with high-growth fundamentals, presenting a potential market leader for growth investors.

Via Chartmill

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

November 11, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...

Via StockStory

Topics Stocks

Insulet Corp (NASDAQ:PODD) Passes Stringent Growth Screen ↗

November 10, 2025

Discover how Insulet Corp exemplifies a powerful growth investing system, showcasing strong earnings, soaring sales, and impressive cash flow.

Via Chartmill

Gapping S&P500 stocks in Thursday's session ↗

November 06, 2025

Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Thursday. Stay informed about the latest market trends.

Via Chartmill

Insulet Rises As Broad Omnipod Growth Stokes Beat-And-Raise Quarter ↗

November 06, 2025

Insulet stock rose moderately early Thursday as its insulin pump, Omnipod, delivered double-digit growth in the U.S. and abroad.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.